ReviewSeminars in oncology2015
Immune checkpoint blockade and interferon-α in melanoma.
Review in Seminars in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.Cancer immunology, immunotherapy : CII · 2018Trial
- The evolution of cancer therapies and their Implications for health technology assessment in Australia.Cost effectiveness and resource allocation : C/E · 2026Review
- Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma.Cancers · 2024Review
- Targeting inflammation as cancer therapy.Journal of hematology & oncology · 2024Review
- Recent advancements in the diagnosis and treatment of acral melanoma.Journal of Zhejiang University. Science. B · 2024Review
- FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma.Brain tumor pathology · 2024Article
- Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway.International journal of molecular sciences · 2023Review
- FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.Seminars in nuclear medicine · 2020Review
- Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.Journal of immunology research · 2020Review
- Prognostic implication and functional annotations of APOBEC3G expression in patients with Melanoma.Journal of Cancer · 2020Article
- Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation.Cancer immunology, immunotherapy : CII · 2019Review
- Review
- Enhanced Antitumor Immune Response in 2'-5' Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy.Journal of immunology research · 2019Article
- Diagnosis and Management of Acral Lentiginous Melanoma.Current treatment options in oncology · 2018Review
- Melanoma treatment in review.ImmunoTargets and therapy · 2018Review
- Changes of Th1/Th2 cytokines in patients with primary hepatocellular carcinoma after ultrasound-guided ablation.International journal of clinical and experimental pathology · 2017Article
- VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.Cancer immunology research · 2016Article
- IFN-λ cancer immunotherapy: new kid on the block.Immunotherapy · 2016Review
- Adverse Events of Oncologic Immunotherapy and Their Management.Asia-Pacific journal of oncology nursingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The quality of the host immune response in patients with advanced melanoma is compromised with a bias towards Th2-type polarization and a tumor microenvironment that facilitates disease progression. Overcoming tumor-induced immune suppression through strategies that build upon the immunomodulatory qualities and clinical activity of interferon-α as demonstrated in the melanoma adjuvant setting is a major clinical need. The recent advances in the field of immune checkpoint modulation and the unprecedented clinical activity in advanced melanoma opens the door on novel combinations that may overcome tumor tolerogenic mechanisms that are known to suppress the potent anti-tumor impact of interferon (IFN)-α. Promising preliminary data suggest that such combinations may move the clinical management of advanced melanoma into the next level, beyond what is currently seen with immune checkpoint blockers alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.